Innovation Pathway? Why Not Fix Expedited Review, AdvaMed Suggests
This article was originally published in The Gray Sheet
Executive Summary
FDA should improve its existing expedited review process for medical devices before investing its limited resources in a brand new innovation pathway, AdvaMed says.
You may also be interested in...
Start-Up FDA? CDRH Seeks Entrepreneurial Spirit With New “In-Residence” Program
CDRH is hoping to inject a dose of start-up-firm mentality into its processes with the official launch last week of the entrepreneurs-in-residence pilot program as part of a broader FDA push to highlight its “innovation” bona fides.
Start-Up FDA? CDRH Seeks Entrepreneurial Spirit With New “In-Residence” Program
CDRH is hoping to inject a dose of start-up-firm mentality into its processes with the official launch last week of the entrepreneurs-in-residence pilot program as part of a broader FDA push to highlight its “innovation” bona fides.
CDRH's Innovation Pathway: A Quicker Route For Breakthrough Devices?
For a select few devices per year, FDA says it will speed up pre-market development times by intensifying staff efforts, with a particular focus on very early-stage, frequent interactions with product sponsors.